Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Total Non-current Assets
All assets not expected to be converted to cash within one year.
Actuate Therapeutics IncNASDAQ: ACTU
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets rises 67.1% from a year ago
Total non-current assets stood at $391.84K at the end of Q1 FY2026, up 67.1% from a year earlier and down 0.2% from the prior quarter.
Context
- Total non-current assets amounted to 4.4% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +67.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 392.49K USD
- Year-over-year change
- +255.0%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 392.49K | +255.0% |
| FY2024 | 2024-12-31 | 110.55K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Total Non-current Assets vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +67.1% is the highest of 9, against a peer median of -24.0%.
- Total non-current assets amounts to 4.4% of total assets for ACTU, versus a peer median of 12.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $136.19M USD | -31.6% | +2.7% | 36.6% | |
| Mar 2026 | $85.78M USD | -12.6% | -16.8% | 72.9% | |
| Mar 2026 | $24.83M USD | -40.4% | -24.1% | 10.4% | |
| Mar 2026 | $22.02M USD | -16.4% | -9.9% | 14.1% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $6.49M USD | -10.0% | -18.2% | 28.6% |
| Mar 2026 | $5.97M USD | -86.6% | -54.1% | 1.2% | |
| Mar 2026 | CHF 4.72M CHF | +13.8% | -11.3% | 5.4% | |
| Mar 2026 | $1.41M USD | -53.0% | -53.0% | 2.4% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $391.84K USD | +67.1% | — | 4.4% |
| Peer median (excluding ACTU) | — | -24.0% | -17.5% | 12.2% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.